A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY

被引：4
|
作者：
Aggarwal, R. [1 ]
Charles-Schoeman, C. [2 ]
Schessl, J. [3 ]
Bata-Csorgo, Z. [4 ]
Dimachkie, M. [5 ]
Griger, Z. [6 ]
Moiseev, S. [7 ]
Oddis, C. V. [8 ]
Schiopu, E. [9 ]
Vencovsky, J. [10 ]
Beckmann, I. [11 ]
Levine, T. [12 ]
Clodi, E. [13 ]
机构：
[1] Univ Pittsburgh, Rheumatol, Pittsburgh, PA USA
[2] UCLA Hlth, Rheumatol, Los Angeles, CA USA
[3] Univ Munich, Friedrich Baur Inst, Neurol, Munich, Germany
[4] Univ Szeged, Fac Med, Dermatol, Szeged, Hungary
[5] Univ Kansas, Med Ctr, Neurol, Kansas City, KS USA
[6] Univ Debrecen, Dept Internal Med, Debrecen, Hungary
[7] First Moscow State Med Univ, Dept Internal Med, Moscow, Russia
[8] Univ Pittsburgh, Rheumatol, Pittsburgh, PA USA
[9] Michigan Med, Rheumatol, Ann Arbor, MI USA
[10] Charles Univ Prague, Rheumatol, Prague, Czech Republic
[11] Clin R&D, Octapharma PPG, Vienna, Austria
[12] Phoenix Neurol Associates, Neurol, Phoenix, AZ USA
[13] Global Med Sci Affairs, Octapharma PPG, Vienna, Austria
[14] Hosp different countries worldwide, Rheumatol Dermatol Neurol, Vienna, Austria
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1389
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0008
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester
    Schiopu, Elena
    Vencovsky, Jiri
    Irene, Beckmann
    Elisabeth, Clodi
    Levine, Todd
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] THE PRODERM STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG (OCTAGAM 10%) IN PATIENTS WITH ACTIVE DERMATOMYOSITIS
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M. M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beck-Mann, I.
    Clodi, E.
    Levine, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 428 - 429
  • [3] Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester
    Schiopu, Elena
    Vencovsky, Jiri
    Beckmann, Irene
    Clodi, Elisabeth
    Levine, Todd
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1409 - 1412
  • [4] Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Dimachkie, Mazen M.
    Beckmann, Irene
    Levine, Todd
    MEDICINE, 2021, 100 (01) : E23677
  • [5] The ProDERM study: A randomized, double-blinded, placebo controlled trial of IVIG (Octagam 10%) in patients with dermatomyositis
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M.
    Griger, Z.
    Moiseev, S.
    Oddis, C.
    Schiopu, E.
    Vencovsky, J.
    Beckmann, I.
    Clodi, E.
    Levine, T.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S133 - S133
  • [6] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Inman, Robert D.
    Davis, John C., Jr.
    van der Heijde, Desiree
    Dickman, Laura
    Sieper, Joachim
    Kim, Sung Il
    Mack, Michael
    Han, John
    Visvanathan, Sudha
    Xu, Zhenhua
    Su, Benjamin
    Beutler, Anna
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
  • [7] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
    Kopecky, E.
    O'Connor, M.
    Varanasi, R.
    Saim, S.
    Fleming, A.
    JOURNAL OF PAIN, 2015, 16 (04): : S87 - S87
  • [8] Efficacy of intravenous immunoglobulins (IVIG) in improving muscle and skin symptoms in dermatomyositis patients. Results of a large, randomized, placebo-controlled international phase III trial (ProDERM)
    Werth, Victoria
    Worm, Margitta
    Aggarwal, Rohit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB53 - AB53
  • [9] EFFICACY AND SAFETY OF CREATINE SUPPLEMENTATION IN JUVENILE DERMATOMYOSITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL
    Solis, Marina Yazigi
    Hayashi, Ana Paula
    Artioli, Guilherme Giannini
    Roschel, Hamilton
    Sapienza, Marcelo Tatit
    Otaduy, Maria Concepcion
    De Sa Pinto, Ana Lucia
    Silva, Clovis Artur
    Elias Sallum, Adriana Maluf
    Pereira, Rosa Maria R.
    Gualano, Bruno
    MUSCLE & NERVE, 2016, 53 (01) : 58 - 66
  • [10] The efficacy and safety of eperisone in patients with cervical spondylosis: Results of a randomized, double-blind, placebo-controlled trial
    Bose, K
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (03): : 209 - 213
12345